

USSN 09/924,338

In the claims

Claims 1-17 (cancelled)

18. (currently amended): ~~A composition comprising a~~ An antibody which specifically
reacts with a ~~human IL-11R~~ protein comprising an amino acid sequence from SEQ ID NO:2
selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino
acids 366 to 390, and amino acids 391 to 422.

Claims 19-38 (cancelled)

39. (currently amended): ~~The composition~~ antibody of claim 18, wherein said antibody is
a neutralizing antibody.

40. (currently amended): ~~The composition~~ antibody of claim 18, wherein said
antibody blocks binding of IL-11 to a human IL-11 receptor.

41. (currently amended): ~~The composition~~ antibody of claim 18, wherein said
antibody is a polyclonal antibody.

USSN 09/924,338

42. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody is a monoclonal antibody.

43. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2.

44. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 422.

45. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 365.

46. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422.

47. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~102~~ 112 to 422.

USSN 09/924,338

48. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~102~~ 112 to 365.

49. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 359.

50. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 345.

51. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 324.

52. (currently amended): The ~~composition~~ antibody of claim ~~18~~ 62, wherein said antibody is obtained using as an immunogen a ~~human IL-11R~~ protein with a cysteine residue at the carboxyl terminus, wherein said protein comprises an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

USSN 09/924,338

53. (currently amended): The ~~composition~~ antibody of claim 18- 62, wherein said antibody is obtained using as an immunogen a ~~human IL-11R~~ protein with tyrosine residues replaced with sulfated tyrosine residues.

54. (cancelled)

55. (currently amended): The ~~composition~~ antibody of claim 18 62, wherein said ~~antibody obtained using as an immunogen a human IL-11R protein~~ is conjugated to a hapten.

56. (currently amended): The ~~composition~~ antibody of claim 55, wherein said hapten is keyhole limpet hemocyanin (KLH).

57. (currently amended): A pharmaceutical composition comprising the ~~composition~~ antibody of claim 18 and a pharmaceutically acceptable carrier.

58. (currently amended): A ~~composition comprising a~~ neutralizing ~~monoclonal~~ antibody that binds specifically to ~~an IL-11R protein~~ comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2 from amino acids 26 to 111, SEQ ID NO:2 from amino acids 112 to 365, SEQ ID NO:2 from 366 to 390, and SEQ ID NO:2 from 391 to 422, wherein said neutralizing antibody blocks binding of IL-11 to a human IL-11 receptor.

USSN 09/924,338

59. (previously added): A pharmaceutical composition comprising the composition of claim 58 and a pharmaceutically acceptable carrier.

60. (newly added): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising an amino acid sequence of SEQ ID NO:2 from 26 to 111.

61 (newly added): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising an amino acid sequence of SEQ ID NO:2 from 366 to 390.

62 (newly added): An antibody obtained using as an immunogen a protein comprising an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

ib
63 (newly added): The antibody of claim 18, wherein said antibody is an isolated antibody.

64 (newly added): The antibody of claim 58, wherein said antibody is an isolated antibody.

65 (newly added): The antibody of claim 62, wherein said antibody is an isolated antibody.
